Form 4: FMR LLC Reduces Stake in Structure Therapeutics

FMR LLC, a significant shareholder, reported multiple sales of American Depositary Shares in Structure Therapeutics Inc. on January 15, 2026, reducing its indirect beneficial ownership.

Summary

• FMR LLC, a 10% owner of Structure Therapeutics Inc. (GPCR), reported multiple sales of American Depositary Shares (ADS) on January 15, 2026.
• The sales were executed through F-Prime Capital Partners Life Sciences Advisors Fund VI LP and F-Prime Capital Partners Life Sciences Fund VI LP.
• A total of 17,452 American Depositary Shares were sold across various price points.
• These sales represent a total of 52,356 Ordinary Shares, as each ADS represents three Ordinary Shares.
• The weighted average sale prices for the ADSs ranged from $82.10 to $85.04.
• Following these transactions, FMR LLC indirectly beneficially owns 1,515,558 American Depositary Shares, which represent 4,546,674 Ordinary Shares.
• Additionally, FMR LLC indirectly beneficially owns 20,502 non-derivative Ordinary Shares through F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 241,275 non-derivative Ordinary Shares through F-Prime Capital Partners Life Sciences Fund VI LP.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a major shareholder, which is generally viewed negatively by the market as it can signal a lack of confidence or a belief that the stock is overvalued.

Negatives

• FMR LLC, a 10% owner, significantly reduced its indirect beneficial ownership in Structure Therapeutics Inc. by selling 17,452 American Depositary Shares (representing 52,356 Ordinary Shares).
• The sales occurred across various price points ranging from $82.10 to $85.04 per ADS, indicating a strategic reduction of exposure by a major shareholder.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May perceive the insider selling as a negative signal, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The significant selling by a 10% owner, FMR LLC, suggests that a major institutional investor is reducing its exposure to Structure Therapeutics Inc. This insider selling, especially across multiple price points, could indicate a belief that the stock's current valuation is high or that future prospects are less favorable. For a seasoned investor, such a move by a well-informed entity like FMR LLC would typically be a strong signal to consider reducing or exiting positions.

Keywords

FMR LLC, Structure Therapeutics, GPCR, Form 4, Insider Trading, Share Sale, American Depositary Shares, Beneficial Ownership